Our South African Chief Scientist and Senior Quality Control Manager (and inventors of Rejuveinix) Henk and Mariette van Wyk formally received their permanent residence Green Cards.
The Reven team is proud to announce their latest US patent allowance, titled “Methods of Treating or Ameliorating Diseases and Enhancing Performance Comprising the use of a Magnetic Dipole Stabilized Solution”. This patent gives us the future opportunity to expand beyond cardiovascular disease while strongly protecting our research and development on many medical conditions such [...]
Investigational New Drug (IND) submitted to FDA. Formal evaluation and FDA collaboration continue to create human clinical trial protocols.
Furthered discussions with esteemed medical centers to begin multi-center Phase I/II trials.
Reven begins Investigational New Drug (IND) process with FDA.
Our chief scientist is from South Africa and he was recently approved for a National Interest Waiver visa from the US Citizenship and Immigration Services (USCIS). This process took two years and ultimately, USCIS decided that having our Chief Scientist here in the US was in the national interest of the United States. This is [...]
Reven hires Allie Lopez as Clinical Director.
2015 Year-End Shareholder Update posted to the Investor Portal.
Reven, in conjunction with its research partner, validated six bio analytical assays for its vascular drug, RJX.
The Australian Patent Office allows Reven its first Australian patent.